Prediction of PSA progression in castrate-resistant prostate cancer based on treatment-associated change in tumor burden quantified by 18F-fluorocholine PET/CT

Prediction of PSA progression in castrate-resistant prostate cancer based on treatment-associated change in tumor burden quantified by 18F-fluorocholine PET/CT

Metabolically active tumor volume (MATV) measurements can be applied to 18 F-fluorocholine positron emission tomography/computed tomography (PET/CT) to quantify whole-body tumor burden. This study evaluates the serial application of these measurements as systemic treatment response markers and predi...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of nuclear medicine (1978) Vol. 57; no. 7; pp. 1058 - 1064
Main Authors: Lee, Joohee, Sato, Miles M., Coel, Marc N., Lee, Kyung-Han, Kwee, Sandi A.
Format: Journal Article
Language:English
Published: 16-02-2016
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metabolically active tumor volume (MATV) measurements can be applied to 18 F-fluorocholine positron emission tomography/computed tomography (PET/CT) to quantify whole-body tumor burden. This study evaluates the serial application of these measurements as systemic treatment response markers and predictors of disease progression in patients with castrate-resistant prostate cancer (CRPC).
ISSN:0161-5505
1535-5667
DOI:10.2967/jnumed.115.169177